177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

NCT04663997 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

200

Enrollment

NETWORK

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: 177Lu-PSMA-617
DRUG: Docetaxel

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]
[object Object]